Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

Compare

1,445 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TNDM Analyst Ratings

Moderate Buy

8 Buy

10 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Tandem

Diabetes Care

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TNDM Stock 12 Month Forecast

Average Price Target

$25.88

▲(15.43% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $25.88 with a high forecast of $55.00 and a low forecast of $14.00. The average price target represents a 15.43% change from the last price of $22.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","56":"$56","22.25":"$22.3","33.5":"$33.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,22.25,33.5,44.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,23.163076923076925,25.816153846153846,28.46923076923077,31.122307692307693,33.77538461538462,36.42846153846154,39.08153846153846,41.73461538461538,44.387692307692305,47.04076923076923,49.69384615384615,52.346923076923076,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,20.923076923076923,21.33615384615385,21.74923076923077,22.162307692307692,22.575384615384614,22.98846153846154,23.40153846153846,23.814615384615387,24.22769230769231,24.64076923076923,25.053846153846152,25.466923076923077,{"y":25.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,20.009230769230772,19.50846153846154,19.00769230769231,18.50692307692308,18.006153846153847,17.505384615384617,17.004615384615384,16.503846153846155,16.003076923076925,15.502307692307692,15.001538461538463,14.500769230769231,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$25.88

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Newitter

Truist Financial

$17→$24

Hold

7.05%

Upside

Reiterated

12/18/25

Tandem Diabetes price target raised to $24 from $17 at TruistTandem Diabetes price target raised to $24 from $17 at Truist

Anthony Petrone

Mizuho Securities

$18→$21

Hold

-6.33%

Downside

Reiterated

12/17/25

Tandem Diabetes price target raised to $21 from $18 at MizuhoTandem Diabetes price target raised to $21 from $18 at Mizuho

William Plovanic

Canaccord Genuity

$24→$35

Buy

56.11%

Upside

Reiterated

12/17/25

Tandem Diabetes price target raised to $35 from $24 at CanaccordTandem Diabetes price target raised to $35 from $24 at Canaccord

Shagun Singh Chadha

RBC Capital

$25→$30

Buy

33.81%

Upside

Reiterated

12/17/25

Tandem Diabetes price target raised to $30 from $25 at RBC CapitalTandem Diabetes price target raised to $30 from $25 at RBC Capital

Jeff Johnson

Robert W. Baird

$18→$30

Buy

33.81%

Upside

Upgraded

12/16/25

Tandem Diabetes upgraded to Outperform from Neutral at BairdTandem Diabetes upgraded to Outperform from Neutral at Baird

Joanne Wuensch

Citi

$16→$22

Hold

-1.87%

Downside

Reiterated

12/12/25

Citi ups Tandem target, adds 'downside 90-day catalyst watch'Citi ups Tandem target, adds 'downside 90-day catalyst watch'

Larry Biegelsen

Wells Fargo

$14→$21

Hold

-6.33%

Downside

Reiterated

12/12/25

Wells Fargo Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Lee Hambright

Bernstein

Hold

―

Reiterated

12/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Kestra Medical Technologies Ltd. (NASDAQ: KMTS) and Ascentage Pharma Group International Unsponsored ADR (NASDAQ: AAPG)

Patrick Wood

Morgan Stanley

$17→$23

Hold

2.59%

Upside

Reiterated

12/02/25

Tandem Diabetes price target raised to $23 from $17 at Morgan StanleyTandem Diabetes price target raised to $23 from $17 at Morgan Stanley

Matt Miksic

Barclays

$55

Buy

145.32%

Upside

Reiterated

11/19/25

Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)

Matthew Taylor

Jefferies

$48

Buy

114.09%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Lemaitre Vascular (NASDAQ: LMAT) and Shattuck Labs (NASDAQ: STTK)

Suraj Kalia

Oppenheimer

$22

Buy

-1.87%

Downside

Reiterated

11/07/25

Tandem Diabetes Care (TNDM) Receives a Buy from Oppenheimer

Jonathan Block

Stifel Nicolaus

$15→$16

Hold

-28.64%

Downside

Reiterated

11/07/25

Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Frank Takkinen

Lake Street

$12→$14

Hold

-37.56%

Downside

Reiterated

11/07/25

Lake Street Sticks to Its Hold Rating for Tandem Diabetes Care (TNDM)

David Roman

Goldman Sachs

$14→$16

Hold

-28.64%

Downside

Reiterated

11/07/25

Goldman Sachs Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Newitter

Truist Financial

$17→$24

Hold

7.05%

Upside

Reiterated

12/18/25

Tandem Diabetes price target raised to $24 from $17 at TruistTandem Diabetes price target raised to $24 from $17 at Truist

Anthony Petrone

Mizuho Securities

$18→$21

Hold

-6.33%

Downside

Reiterated

12/17/25

Tandem Diabetes price target raised to $21 from $18 at MizuhoTandem Diabetes price target raised to $21 from $18 at Mizuho

William Plovanic

Canaccord Genuity

$24→$35

Buy

56.11%

Upside

Reiterated

12/17/25

Tandem Diabetes price target raised to $35 from $24 at CanaccordTandem Diabetes price target raised to $35 from $24 at Canaccord

Shagun Singh Chadha

RBC Capital

$25→$30

Buy

33.81%

Upside

Reiterated

12/17/25

Tandem Diabetes price target raised to $30 from $25 at RBC CapitalTandem Diabetes price target raised to $30 from $25 at RBC Capital

Jeff Johnson

Robert W. Baird

$18→$30

Buy

33.81%

Upside

Upgraded

12/16/25

Tandem Diabetes upgraded to Outperform from Neutral at BairdTandem Diabetes upgraded to Outperform from Neutral at Baird

Joanne Wuensch

Citi

$16→$22

Hold

-1.87%

Downside

Reiterated

12/12/25

Citi ups Tandem target, adds 'downside 90-day catalyst watch'Citi ups Tandem target, adds 'downside 90-day catalyst watch'

Larry Biegelsen

Wells Fargo

$14→$21

Hold

-6.33%

Downside

Reiterated

12/12/25

Wells Fargo Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Lee Hambright

Bernstein

Hold

―

Reiterated

12/12/25

Patrick Wood

Morgan Stanley

$17→$23

Hold

2.59%

Upside

Reiterated

12/02/25

Tandem Diabetes price target raised to $23 from $17 at Morgan StanleyTandem Diabetes price target raised to $23 from $17 at Morgan Stanley

Matt Miksic

Barclays

$55

Buy

145.32%

Upside

Reiterated

11/19/25

Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)

Matthew Taylor

Jefferies

$48

Buy

114.09%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Lemaitre Vascular (NASDAQ: LMAT) and Shattuck Labs (NASDAQ: STTK)

Suraj Kalia

Oppenheimer

$22

Buy

-1.87%

Downside

Reiterated

11/07/25

Tandem Diabetes Care (TNDM) Receives a Buy from Oppenheimer

Jonathan Block

Stifel Nicolaus

$15→$16

Hold

-28.64%

Downside

Reiterated

11/07/25

Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Frank Takkinen

Lake Street

$12→$14

Hold

-37.56%

Downside

Reiterated

11/07/25

Lake Street Sticks to Its Hold Rating for Tandem Diabetes Care (TNDM)

David Roman

Goldman Sachs

$14→$16

Hold

-28.64%

Downside

Reiterated

11/07/25

Goldman Sachs Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

1 Month

xxx

Success Rate

15/22 ratings generated profit

Average Return

+7.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.18% of your transactions generating a profit, with an average return of +7.62% per trade.

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

+55.76%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +55.76% per trade.

1 Year

Matt MiksicBarclays

Success Rate

10/16 ratings generated profit

Average Return

+5.34%

reiterated a buy rating 30 days ago

Copying Matt Miksic's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +5.34% per trade.

2 Years

xxx

Success Rate

10/17 ratings generated profit

Average Return

+91.72%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +91.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TNDM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TNDM has received 12 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. TNDM average Analyst price target in the past 3 months is 25.88.

Each month's total comprises the sum of three months' worth of ratings.

TNDM Financial Forecast

TNDM Earnings Forecast

Next quarter’s earnings estimate for TNDM is -$0.08 with a range of -$0.28 to $0.05. The previous quarter’s EPS was -$0.31. TNDM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TNDM has Performed in-line its overall industry.

TNDM Sales Forecast

Next quarter’s sales forecast for TNDM is $276.75M with a range of $271.43M to $281.86M. The previous quarter’s sales results were $249.25M. TNDM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TNDM has Performed in-line its overall industry.

TNDM Stock Forecast FAQ

What is TNDM’s average 12-month price target, according to analysts?

Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 25.88.

What is TNDM’s upside potential, based on the analysts’ average price target?

Tandem Diabetes Care has 15.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TNDM a Buy, Sell or Hold?

Tandem Diabetes Care has a consensus rating of Moderate Buy which is based on 8 buy ratings, 10 hold ratings and 0 sell ratings.

What is Tandem Diabetes Care’s price target?

The average price target for Tandem Diabetes Care is 25.88. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $14.00. The average price target represents 15.43% Increase from the current price of $22.42.

What do analysts say about Tandem Diabetes Care?

Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of TNDM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

TNDM Analyst Ratings

TNDM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tandem Diabetes Care

TNDM Analyst Recommendation Trends

TNDM Financial Forecast

TNDM Earnings Forecast

TNDM Sales Forecast

TNDM Stock Forecast FAQ

Detailed List of Analyst Forecasts